ADAM10 and melanoma: The above distinctions have therapeutic relevance: (i) inhibiting ADAM10/17 and designing neurexin–ligand-binding molecules will likely decrease the degree of support provided by the neural environment to melanoma cells but (ii) will likely act on a broader axis of neuron-derived trophic signals rather than directly acting on a neuron–melanoma synapse [183].